Flybridge Capital Partners invests in capital efficient healthcare technology companies with a core focus on companies that address the convergence of healthcare and technology. From connected health to personalized medicine to drug / device delivery platforms, intelligent devices, diagnostics and detection, and healthcare infrastructure we look to invest in world-class scientists, entrepreneurs and innovators who are building life-changing healthcare companies and products.
Acquired by 3M in October 2006, Brontes changes the way dentists treat their patients by enabling practitioners to perform ImpressionFreeTM dentistry. Brontes’ 3D intraoral imaging technology quickly and painlessly scans both arches of the mouth, thereby replacing the antiquated dental impression process. The company was founded in 2003 based on the research of Dr. János Rohály, Professor Douglas Hart and two graduate students from the Department of Mechanical Engineering at the Massachusetts Institute of Technology, Eric Paley and Micah Rosenbloom.
Acquired by PPD in April 2009, Magen BioSciences focuses on improving the health and appearance of human skin. Magen pursues a science-driven approach to identify and develop novel therapeutics to treat a number of large, poorly served dermatological disorders. The company has assembled an outstanding science, investor and management team. The team includes co-founders of Idexx, Immunex, Alnylam, Momenta, Vertex, Biogen and Genzyme.
MicroCHIPS, Inc. is pioneering the next generation of implantable drug delivery and biosensing devices for use in the pharmaceutical and patient monitoring markets. Our proprietary reservoir technologies include both active and passive forms and provide numerous product opportunities for our partners. MicroCHIPS, Inc. is a privately held company headquartered in Bedford, Massachusetts. The Company was founded in 1999 by Dr. John Santini, MIT Professors Michael Cima and Robert Langer, and Terry McGuire of Polaris Venture Partners. Our world-class team of twenty-nine includes the best and brightest scientists and engineers in the fields of drug formulation, biosensor development, materials science and microelectronics.
As an innovator, creator and leading supplier of integrated physician information systems, PatientKeeper's applications provide a single point of anytime, anywhere access to clinical and financial data from multiple, disparate systems. PatientKeeper's technology automates the provider’s day to transform their experience and improve satisfaction. The Company’s physician-centric portal and mobile applications improve user satisfaction and patient safety, increase revenue and simplify data access and interoperability for community health information exchange.
PolyRemedy, Inc. manufactures robotic systems for the fabrication of nano-material based wound dressings at the point-of-care, allowing wound care clinicians to easily and cost-effectively deliver customized wound care on-demand for each patient’s unique wound.
Leveraging its portfolio of patented urinary protein biomarkers and clinical algorithms, Predictive Biosciences is pioneering intervention diagnostic assays for informed cancer management™. The company’s proprietary clinical algorithms, which deliver exceptionally high negative predictive value (NPV) and positive predictive value (PPV), can be applied to significantly enhance the performance of biomarkers and diagnostic assays. Predictive Biosciences is initially focused on diagnostics for the precise management of cancer survivors.
Acquired by Cell Biosciences in December 2009. Protein Forest, Inc. (founded in 2002) is a proteomics tools company located in Lexington, Massachusetts. The company develops, manufactures and markets instruments, consumables and software products to scientists around the world. The initial product lines utilize a new technology called parallel isoelectric focusing which is incorporated into the digital ProteomeChip™ (dPC™).
Sciformix is a US headquartered Knowledge Process Outsourcing company whose aim is to deliver high quality knowledge-based services using a cost-optimized global delivery model. The company delivers specialized services of the highest quality in global Drug Safety Data Management, Clinical Data Management, Biostatistics and Medical Writing. Founded by two experienced professionals, Sciformix's core team comprises of industry experts in drug safety, epidemiology, labeling, biostatistics, and medical affairs. Sciformix management has the unique combination of internal experience in global pharmaceutical companies and building organizations delivering specialized services from India.
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers including Robert Langer, PhD, Michael Cima, PhD and Tyler Jacks, PhD from the Massachusetts Institute of Technology, and Ralph Weissleder, MD and PhD and Lee Josephson, PhD from Massachusetts General Hospital.
TARIS Biomedical Inc., a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products. The TARIS core technology and development efforts are being applied to disease areas with high unmet medical need in which current therapies or systemic treatments have failed. TARIS Biomedical has several drug-device convergence program opportunities focused on addressing those underserved disease areas through local delivery of therapeutics, with an initial focus on bladder diseases including Interstitial Cystitis (IC)/Painful Bladder Syndrome (PBS).